Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide + CAG + DLI for high-risk or relapsed hematologic malignancies after allogeneic stem cell transplantation
ChiCTR1800017740Phase 2Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Aug 2018
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat, cytarabine, aclarubicin and granulocyte colony-stimulating factor in Acute Leukaemia and myelodysplastic syndrome (MDS), sponsored by Chinese PLA General Hospital. Primary endpoints: complete remission and partial remission. Started Aug 2018; status: recruiting.
02
Drugs
tucidinostatcytarabineaclarubicingranulocyte colony-stimulating factor
03
Conditions
Acute Leukaemiamyelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on ChiCTR1800017740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800017740.